Real-time PCR PCA3 assay is a useful test measured in urine to improve prostate cancer detection

Clinica Chimica Acta

Volumn 435, Issue , 2014, Pages 53-58

  Foj, Laura ^a   Milà, Montserrat ^a   Mengual, Lourdes ^a   Luque, Pilar ^a   Alcaraz, Antonio ^a   Jiménez, Wladimiro ^a   Filella, Xavier ^a  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

Author keywords

PCA3; Prostate cancer; PSA; Urinary biomarkers

Indexed keywords

TUMOR MARKER;

AGED; ARTICLE; CANCER DIAGNOSIS; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MOLECULAR DYNAMICS; ONCOGENE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER ANTIGEN 3 GENE; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SENSITIVITY ANALYSIS; URINALYSIS;

EID: 84901044470     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2014.04.025     Document Type: Article

References (34)

1. Ferlay J., Steliarova-Foucher E., Lortet-Tieulent J., et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013, 49:1374-1403.
2. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999, 59:5975-5979.
3. Salagierski M., Schalken J.A. Molecular diagnosis of prostate cancer: PCA3 and TMPRSS2:ERG gene fusion. J Urol 2012, 187:795-801.
4. Clarke R.A., Zhao Z., Guo A.Y., et al. New genomic structure for prostate cancer specific gene PCA3 within BMCC1: implications for prostate cancer detection and progression. PLoS One 2009, 4:e4995.
5. Roobol M.J. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol 2011, 21:225-229.
6. Filella X., Foj L., Milà M., Augé J.M., Molina R., Jiménez W. PCA3 in the detection and management of early prostate cancer. Tumour Biol 2013, 34:1337-1347.
7. Dijkstra S., Mulders P.F., Schalken J.A. Clinical use of novel urine and blood based prostate cancer biomarkers: a review. Clin Biochem Oct 29 2013, [pii: S0009-9120(13)00497-9].
8. Chevli K.K., Duff M., Walter P., et al. Urinary PCA3 as a predictor for prostate cancer in a cohort of 3073 men undergoing initial prostate biopsy. J Urol Dec 10 2013, [pii: S0022-5347(13)06087-4].
9. DeLong E.R., DeLong D.M., Clarke-Pearson D.L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988, 44:837-845.
10. Truong M., Yang B., Jarrard D.F. Toward the detection of prostate cancer in urine: a critical analysis. J Urol 2013, 189:422-429.
11. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006, 52:1089-1095.
12. Sokoll L.J., Ellis W., Lange P., et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta 2008, 389:1-6.
13. Haese A., de la Taille A., van Poppel H., et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008, 54:1081-1088.
14. de la Taille A., Irani J., Graefen M., et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol 2011, 185:2119-2125.
15. Perdonà S., Bruzzese D., Ferro M., et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate 2013, 73:227-235.
16. Ferro M., Bruzzese D., Perdonà S., et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta 2012, 413:1274-1278.
17. Stephan C., Jung K., Semjonow A., et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2] proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem 2013, 59:280-288.
18. Auprich M., Augustin H., Budäus L., et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int 2012, 109:1627-1635.
19. Bradley L.A., Palomaki G.E., Gutman S., Samson D., Aronson N. Comparative effectiveness review: prostate cancer antigen 3 testing for the diagnosis and management of prostate cancer. J Urol 2013, 190:389-398.
20. Crawford E.D., Rove K.O., Trabulsi E.J., et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol 2012, 188:1726-1731.
21. Capoluongo E., Zambon C.F., Basso D., et al. PCA3 score of 20 could improve prostate cancer detection: results obtained on 734 Italian individuals. Clin Chim Acta 2013, 429C:46-50.
22. Rigau M., Morote J., Mir M.C., et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate 2010, 70:1760-1767.
23. Salami S.S., Schmidt F., Laxman B., et al. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2013, 31:566-571.
24. Chun F.K., de la Taille A., van Poppel H., et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol 2009, 56:659-667.
25. Rubio-Briones J., Fernández-Serra A., Ramírez M., et al. Outcomes of expanded use of PCA3 testing in a Spanish population with clinical suspicion of prostate cancer. Actas Urol Esp 2011, 35:589-596.
26. Klotz L. Active surveillance for prostate cancer: overview and update. Curr Treat Options Oncol 2013, 14:97-108.
27. Ferro M., Bruzzese D., Perdonà S., et al. Prostate Health Index (Phi) and prostate cancer antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10ng/ml. PLoS One 2013, 8:e67687.
28. Nakanishi H., Groskopf J., Fritsche H.A., et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol 2008, 179:1804-1809.
29. van Poppel H., Haese A., Graefen M., et al. The relationship between prostate cancer gene 3 (PCA3) and prostate cancer significance. BJU Int 2012, 109:360-366.
30. Durand X., Xylinas E., Radulescu C., et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int 2012, 110:43-49.
31. Augustin H., Mayrhofer K., Pummer K., Mannweiler S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate 2013, 73:203-210.
32. Hessels D., van Gils M.P., van Hooij O., et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate 2010, 70:10-16.
33. Ploussard G., Durand X., Xylinas E., et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol 2011, 59:422-429.
34. van Gils M.P., Hessels D., Hulsbergen-van de Kaa C.A., et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate 2008, 68:1215-1222.